Abstract
In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adenoviridae / genetics
-
Animals
-
Anti-Inflammatory Agents / therapeutic use*
-
Anticarcinogenic Agents / therapeutic use
-
Apoptosis / drug effects
-
Bexarotene
-
Budesonide / therapeutic use*
-
Cell Proliferation / drug effects
-
Disease Models, Animal*
-
Female
-
Genetic Engineering*
-
Immunoenzyme Techniques
-
In Situ Nick-End Labeling
-
Integrases / metabolism
-
Lung Neoplasms / prevention & control*
-
Male
-
Mice
-
Mice, Inbred A
-
Retinoblastoma Protein / physiology
-
Small Cell Lung Carcinoma / prevention & control*
-
Tetrahydronaphthalenes / therapeutic use*
-
Tumor Suppressor Protein p53 / physiology
Substances
-
Anti-Inflammatory Agents
-
Anticarcinogenic Agents
-
Retinoblastoma Protein
-
Tetrahydronaphthalenes
-
Tumor Suppressor Protein p53
-
Budesonide
-
Bexarotene
-
Cre recombinase
-
Integrases